Drugs / KBP-336
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06833749 Comparator | Jan 2025 → Nov 2026 expected | obesity disorder, osteoarthritis, knee | KeyBioscience AG | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KBP-336 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06833749 ↗ |
| Action | Activate | “KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist” NCT06833749 ↗ |
| Route | Subcutaneous | “weekly administration through subcutaneous injection” NCT06833749 ↗ |